Education
Post Doctoral Fellowship, Harvard Medical School
PhD, State University of New York at Buffalo
MS, Emory University
Background
Daniel R. Kennedy received his B.S. and M.S. degrees in Chemistry from Emory University and his Ph.D. in Molecular Pharmacology and Experimental Therapeutics from the State University of New York at Buffalo–Division of the Roswell Park Cancer Institute. Before joining 网曝门 University, he instructed a wide variety of science courses at Emmanuel College while completing a post-doctoral fellowship at Harvard Medical School in the areas of hemostasis and thrombosis.
At WNE, he has instructed in 16 distinct courses, primarily in Pharmacology and Pathophysiology. He was named a Distinguished Teaching Scholar by the American Association of Colleges of Pharmacy in 2025 and has mentored over 50 graduate, PharmD or undergraduate students on research projects, and his students have won national poster competitions in 2018 and 2024.
Dr. Kennedy’s current laboratory research focus utilizes high throughput screening methodologies to identify broad spectrum thiol isomerase inhibitors and explore their roles in cancer, thrombosis, and cancer induced thrombosis. His research work has been continuously funded by external sources since 2014, resulting in 35 manuscripts and seven patents, 3 of which are licensed. He also holds academic appointments at the UMass Chan Medical School – Baystate and at the University of Reading.
Beyond the laboratory, Dr. Kennedy has explored multiple projects in the scholarship of teaching and learning and best practices in pharmacy education, publishing over 15 manuscripts in these areas and serving as an Editorial Board Member of the American Journal of Pharmaceutical Education. He is an active member of the American Society of Pharmacology and Experimental Therapeutics, International Society of Thrombosis and Hemostasis and the American Association of Colleges of Pharmacy, the latter of which he has held many leadership positions in throughout his career, including Chair of the Biological Sciences Section and was recently awarded a Distinguished Service Award for his work within that section.
Scholarly Works
Select Peer-Reviewed Articles: (Last 5 Years)
* indicates student co-author
Laboratory Based
*Gelzinis JA, *Howard KC, Taylor KA, Khan S, *Wurl SE, Szahaj MK, Sage T, Chandrika NT, Hou C, Tsodikov O, Gibbins JM, Garneau-Tsodikova S, Kennedy DR. Development of zafirlukast analogues for improved anti-thrombotic activity through thiol isomerase inhibition. Arteriosclerosis, Thrombosis & Vascular Biology – 2024 45(4) 10.1161/ATVBAHA.124.321579
*Gelzinis JA, Szahaj MK, Bekendam RH, *Wurl SE, *Pantos MM, *Verbetsky CA, Dufresne A, Shea M, *Howard KC, Tsodikov O, Garneau-Tsodikova S, Zwicker JI, Kennedy DR. Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic. FASEB Journal – 2023 37(5) e22914
Holbrook LM, Keeton S, Sasikumar P, Nock S, Gelzinis J, Brunt E, Ryan S, *Pantos MM, *Verbetsky C, Gibbins JM, and Kennedy DR. Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times. British Journal of Pharmacology. – 2021;1–14. https://doi.org/10.1111/bph.15291
Krajewski D, Polukort SH, Gelzinis J, *Rovatti J, *Kaczinski E, *Galinski C, *Pantos MM, Shah NN, Schneider SS, Kennedy DR and Mathias CB. Protein disulfide isomerase inhibition regulates mast cell function conferring protective effects to ingested allergens. Frontiers in Immunology - Front. Immunol. 11:606837.doi: 10.3389/fimmu.2020.606837
Non-laboratory based
Medina M, Stolte S, Conry J, Culhane N, Farland MZ, Kennedy DR, Lockman K, Malcom DR, Mirzaian E, Vyas D, Steinkopf M and Ragucci K. Revising the Center for the Advancement of Pharmacy Education (CAPE) Educational Outcomes and Entrustable Professional Activities (EPAs): The Report of the 2021-2022 Academic Affairs Standing Committee. American Journal of Pharmaceutical Education 2023, 87 (1) Article 9453
Kennedy DR, and Porter AL. The Illusion of Urgency. American Journal of Pharmaceutical Education 2022 86 (7) Article 8914
Prescott WA, Kennedy DR and DeLuca JI. Remote Work in Pharmacy Academia and Implications for the New-Normal. American Journal of Pharmaceutical Education – 2022, 86 (10), Article 8950
Kennedy DR, Clapp P, DeLuca Jl, Filtz TM, Kroon L, Lamberts JT, Oliphant CM, Prescott WA, Ray SD. Enhancing Pharmacy Faculty Well-Being and Productivity while Reducing Burnout. American Journal of Pharmaceutical Education – 2022, 86 (5) Article 8764
*Pantos MM, Kennedy DR, Nemec EC. Remimazolam: a novel option for procedural sedation in high risk patients. Journal of Pharmacy Practice 2021 doi:10.1177/08971900211027303
*Dias ML, *Armstrong KJ, *Pantos MM, Spooner JS, Kennedy DR. Examining Course Credits, Placement, and Integration of Pathophysiology and Anatomy and Physiology within PharmD Curriculum. American Journal of Pharmaceutical Education. 2020, 84 (11) 8025
Kennedy DR, Harrell TK, Lodise NM, Mattingly TJ II, Norenberg JP, Ragucci K, Ranelli P, Stewart AS. Current Status and Best Practices of Shared Governance within US Pharmacy Programs. American Journal of Pharmaceutical Education – 2020, 84 (7) 7281
Kennedy DR, Bond R, Bastianelli KMS, Orr K, Rowe EL, Shealy KM, and MacLean LG. “History has its Eyes on You”: Leadership Lessons from the musical Hamilton. American Journal of Pharmaceutical Education. 2020 – 84 (10) Article 8175
Romanelli F, Black EP, Rhoney DH, Conway J and Kennedy DR. Pharmacy Education Crosses the Rubicon. American Journal of Pharmaceutical Education. 2020 – 84 (6) Article 8131
Kennedy DR, Beckett RD, O’Donnell LA. Strategies, Ideas, And Lessons Learned While Getting Started in SoTL Without Formal Training. American Journal of Pharmaceutical Education. 2020, 84 (1) Article 7702.
